Irbesartan
Angiotensin Ii Receptor Blockers (Arbs), Plain
Sold as Karvea · Aprovel · Sabervel · Karvezide · CoAprovel
- Drug class
- Angiotensin Ii Receptor Blockers (Arbs), Plain
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 195
- FDA reports (12 mo)
- 2,144
Overview
Irbesartan is an active pharmaceutical ingredient in the Angiotensin Ii Receptor Blockers (Arbs), Plain group (C09CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 98 | May 29, 2026 |
| CA Canada | Health Canada | 75 | May 19, 2026 |
| US United States | FDA | 12 | May 13, 2026 |
| EU European Union | EMA | 10 | May 6, 2026 |
GBUnited Kingdom· MHRA
98 products
Uses
Irbesartan is indicated in adults for the treatment of essential hypertension. 1).
How to take
CACanada· Health Canada
75 products
Uses
and 14 CLINICAL TRIALS). The dosage may be increased after 2 - 4 weeks of therapy to a maximum of 300/25 mg once daily. Sandoz Irbesartan HCT is not recommended as initial therapy in patients with intravascular volume depletion (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).
DOSE ADJUSTMENT IN SPECIAL POPULATION Diuretic Treated Patients In patients receiving diuretics, irbesartan therapy should be initiated with caution, since these patients may be volume-depleted and thus more likely to experience hypotension following initiation of additional antihypertensive therapy.
Whenever possible, all diuretics should be discontinued 2 - 3 days prior to the administration of irbesartan to reduce the likelihood of hypotension (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, and 9 DRUG INTERACTIONS). If this is not possible because of the Sandoz Irbesartan HCT (Irbesartan and hydrochlorothiazide) Page 7 of 54 Protected B / Protégé B patient’s condition, irbesartan should be administered with caution and the blood pressure monitored closely.
USUnited States· FDA
12 products
Uses
1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. 1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure.
Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
EUEuropean Union· EMA
10 products
Uses
Ifirmasta is indicated in adults for the treatment of essential hypertension. 1).
How to take
Drug interactions
Known interactions involving Irbesartan. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 484. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL549770005 · revised March 20, 2026
- [2]Health Canada (DPD) · 02337428 · revised November 26, 2025
- [3]FDA DailyMed · 029a90b6-0722-49… · revised January 27, 2026 [PDF]
- [4]European Medicines Agency · EMEA/H/C/000962 · revised May 6, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.